A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
A phase 1/2 trial of AZD7789 in non-small-cell lung cancer and gastric & gastro-oesophageal junction cancer, run by AstraZeneca, active and no longer recruiting.
Overview
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer is a phase 1/2 interventional study registered as NCT04931654 by AstraZeneca, with 136 participants enrolled, started 2021-09-28 and due to reach its primary completion in 2024-12-04. Interventions recorded: AZD7789.
Similar pages
not linked directly; found by shared links- TrialA Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2
Shares AstraZeneca, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
- TrialPhase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
Shares Gastric & gastro-oesophageal junction cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialDurvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
- TrialA Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
Shares AstraZeneca, Gastric & gastro-oesophageal junction cancer and the tag pipeline.